Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years Su-Hyun Kim, MD; Woojun Kim, MD, PhD; Xue Feng Li, MD, MSc; In-Ja Jung, RN; Ho Jin Kim, MD, PhD Arch Neurol. ?2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154 Objective? To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO).
Imaging Immune-Mediated Depression and Cognitive Impairment in Autoimmune Neurologic Diseases: MRS of Patients with Multiple Sclerosis and Transverse Myselitis Adam I. Kaplin, M.D., Ph.D.
Background: Neuromyelitis optica (NMO) is a severe demyelinating disease often leading to serious disability. Accumulating evidence now implicates humoral mechanisms in its pathogenesis.
Background: Based on case series and anecdotal evidence, immunosuppression has been shown to reduce relapse rates and delay disability in Neuromyelitis Optica spectrum disorders (NMOSD) and is currently the mainstay of disease modifying treatment.
Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory demyelinating disorder.